In two large, randomized studies conducted in sub-Saharan Africa, antiretroviral regimens given to lactating mothers or their infants reduced postnatal HIV acquisition.
Treating HIV-infected pregnant women with combination antiretroviral therapy (ART) has nearly eliminated perinatal HIV transmission in the developed world. However, in poor countries, many infected women do not receive ART during pregnancy or lactation. As a result, 430,000 infants acquire HIV each year; of these, approximately 200,000 are infected through breast-feeding. Now, two large trials — one in Botswana and one in Malawi — show that most such postnatal infections can be prevented.
In Botswana, 560 HIV-infected pregnant women with CD4 counts ≥200 cells/mm3 were randomized to receive coformulated abacavir/zidovudine/lamivudine (the nucleoside reverse transcriptase inhibitor [NRTI] group) or lopinavir/ritonavir plus zidovudine/lamivudin…
Reviewing Author
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)